Back to Bigger Picture

BIGGER PICTURE Better care

The promising antibiotic was hiding in a different medicine search

A molecule once investigated for diabetes emerged from an entirely different search. Machine learning helped researchers find its antibacterial potential; targeted experiments then revealed an unusual way to attack a resistant hospital bacterium.

AI-generated illustration: Computational screening narrows a molecular search to an antibacterial candidate.
Computational screening narrows a molecular search to an antibacterial candidate.AI-generated illustration of the idea, not a photograph of the actual people, equipment or event.
Search library
6,680 previously unseen compounds
Laboratory shortlist
240 candidates tested
Evidence stage
Bacterial cultures and a mouse wound model

How the idea works

  1. Learn bacterial inhibition

    Measured bacterial growth links molecular structure to activity.

  2. Prioritise unfamiliar chemistry

    Models and structural filters select a small testable shortlist.

  3. Check the mechanism in biology

    Culture, resistance and animal experiments test the candidate.

One particularly difficult hospital bacterium

Acinetobacter baumannii can resist multiple antibiotics. The MIT–McMaster team first tested thousands of molecules against the bacterium to create training data. Chemical structures were paired with a practical label: did the compound inhibit bacterial growth in the laboratory?

Sources: [1]

Look beyond familiar antibiotic shapes

The trained models scored a separate library of 6,680 compounds. Researchers selected 240 with promising predictions and structures different from known active examples. Laboratory testing yielded nine antibacterial hits. One had previously been investigated for a different purpose, as a potential diabetes medicine.

Sources: [1][2]

Disrupt the bacterium’s internal delivery system

Further experiments linked abaucin’s activity to lipoprotein transport involving the protein LolE. These molecules must reach the bacterial envelope. The compound showed unusually narrow activity against A. baumannii, rather than broadly attacking all the tested bacterial species.

Sources: [1][2]

From a molecular clue to a mouse wound

Abaucin controlled infection in a mouse wound model and worked against resistant isolates in laboratory tests. Those are meaningful experimental results, but not evidence of benefit in human patients. Its larger lesson is how prediction and selective experiments can uncover a new use for overlooked chemistry.

Sources: [1][2]

The original sources

  1. Nature Chemical Biology / MIT author manuscriptDeep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii
  2. MIT NewsUsing AI, scientists find a drug that could combat drug-resistant infections

What to explore next

A brain pacemaker that changes with the medication cycle50,000 public responses became a map analysts could inspect
Explore all 99 applications